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Aims 
To (1) examine the prescribing of preventative medication in a cohort of people with advanced 
lung cancer on hospital admission and discharge across different healthcare systems; (2) 
explore the factors that influence preventative medication prescribing at hospital discharge.   
Methods 
A retrospective cohort study across two centers in the United Kingdom and the United States. 
The prescribing of preventative medication was examined at hospital admission and discharge 
for patients who died of lung cancer; a zero-inflated negative binomial regression model was 
used to exam the association between preventative medications at discharge and patient- and 
hospital-based factors. Classes of preventative medication included: vitamins and minerals, 
anti-diabetic, anti-hypertensive, anti-lipid, and anti-platelet medications. 
Results 
In the UK site (n=125 people), the mean number of preventative medications was 1.9 (SD ± 
1.7) on admission, and 1.7 (SD ± 1.7) on discharge, whilst in the US site (n=191 people) the 
mean was 2.6 (SD ± 2.2) on admission and 1.9 (SD ± 2.2) on discharge. The model found a 
significant association between the number of preventative drugs on admission and the number 
of preventative medications on discharge; the model also found a significant association 
between the total number of drugs on discharge and the number of preventative medications 
on discharge. Other indicators related to patient and hospital factors were not significantly 
associated with preventative medications supplied on discharge. 
Conclusions  
The use of preventative medication was common in lung cancer patients, despite undergoing 
discharge. Patient-based and hospital-based factors did not influence the prescribing of 
preventative medication 
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What is known about this subject? 
 The presence of multi-morbid conditions is highly common in a lung cancer population. 
 It is common for this patient group to have complex, costly and often inappropriate 
medication regimens. 
 This patient group is frequently hospitalized in the last year of life. 
 
What this study adds? 
 The use of preventative medication is common in lung cancer patients is common, 
which is evident across different healthcare systems 
 There is no association between preventative medication at discharge and patient-based 
(e.g stage of cancer), and hospital-based factors (e.g time spent in hospital). 
 Deprescribing interventions directed towards reducing preventative medication use 
could be implemented at the point of hospital discharge. 
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Background 
Lung cancer is the most common cancer in the world with around 1.8 million new cases 
diagnosed annually.[1] It is the most frequent cause of cancer-related mortality, accounting for 
approximately 1.5 million deaths each year – roughly equating to around 1 in 5 of all cancer-
related deaths.[2] Lung cancer, like the majority of other cancers, is predominately a disease 
of older people: around two in three cases are reported in people aged over 65 years, while the 
mean age of diagnosis is 70 years.[3]  
Due to age as well as common risk factors, the presence of multi-morbid conditions – 
including cardiovascular disease, cerebrovascular disease, and chronic  obstructive pulmonary 
disease (COPD) – is highly common in a lung cancer population.[4] The presence of these 
chronic conditions is accompanied by the chronic use of medications to maintain disease 
control or to treat symptoms associated with these conditions or to prevent further worsening 
of them. The overall effect of this paradigm is that polypharmacy is common and the pill burden 
is high amongst this patient group.[5-6] This is challenging, particularly for medication used 
in the context of primary or secondary prevention: a recent systematic review showed that 
many preventative medications are inappropriately prescribed in the context of life limiting 
illnesses, such as lung cancer; the review identified vitamins and minerals, anti-diabetic, anti-
hypertensive, anti-lipid, and anti-platelet medications, as preventative medication with 
questionable benefit.[7] In addition, previous research has also demonstrated that inappropriate 
medication use in a palliative setting could increase the risk of the patient developing severe 
drug-drug interactions, possibly resulting in hospitalization or even death.[8] 
Previous work has shown that lung cancer patients are frequently hospitalized in their 
last year of life – perhaps more so than patients with any other type of cancer.[9] For example, 
Mayer and colleagues showed that out of 37,760 cancer-related Emergency Room (ER) visits, 
26.9% were attributable to lung cancer patients (compared to 6.3%, 6.0%, and 7.7% of visits 
  
This article is protected by copyright. All rights reserved. 
for breast, prostate, and colorectal patients respectively).[10] Common reasons for the 
hospitalization of lung cancer patients included pain, respiratory distress, and GI issues.[10] 
Given this observation, and the fact that lung cancer patients often have complex, costly, and 
burdensome medication regimens, it is not clear how episodes of hospitalization – or prolonged 
periods of time spent in hospital – influence or change a patient’s medication, or indeed, how 
this varies according to healthcare system. In the UK, for example, patients with advanced 
disease receiving cancer therapy may be cared for in hospice care for a significant time before 
death and may still be admitted to the hospital.[11] In the US, patients are referred to hospice 
care late in the disease process, with a median length of stay in hospice of 19 days for patients 
with cancer.[12] We hypothesized that a hospital stay would present an opportunity to reduce 
medications with questionable benefit, and thus, through medicine optimization and hospital 
discharge, it would be more likely that preventative medication would be discontinued. 
This work, therefore, aimed to (1) examine the prescribing of preventative medication 
in a cohort of people with advanced lung cancer on hospital admission and discharge across 
different healthcare systems; and, (2) explore the factors that influence preventative medication 
prescribing at hospital discharge. 
 (1) describe preventative medication prescribing in a cohort of lung cancer patients 
pre- and post- hospital admission across different healthcare systems; and (2) to explore the 
factors that influence preventative medication prescribing at hospital discharge in a cohort of 
lung cancer patients.   
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Methods 
Setting 
To meet our study aims, two tertiary care centers were chosen as sites of data collection: 
MD Anderson Cancer Centre, Houston, Texas, US; and, The Newcastle Hospitals Foundation 
Trust, Newcastle-upon-Tyne, UK. MD Anderson solely focuses on cancer care, and has around 
1.5 million patient contacts per year, with patients who have Medicare, private insurance, or 
other means of healthcare coverage, whilst The Newcastle Hospitals provides all aspects of 
healthcare, including cancer care, and has around 1.7 million patient contacts per year, the vast 
majority of which are managed through the National Health Service (NHS). There are 
approximately 1800 inpatient hospital beds across The Newcastle Hospital Foundation Trust 
and, for MD Anderson, there are around 600 inpatient beds.[13-14] Study approval and 
registration was obtained from each site: as this was a retrospective study on deceased patients, 
this work was considered ‘not human subject research’ as defined by the Federal Regulations. 
In view of this, full IRB approval was not required, and The Waivers of Informed Consent and 
Authorization were granted. 
 
Design 
This was a retrospective cohort study of medication use at hospital admission and 
hospital discharge during the hospitalization prior to death for patients who died of lung cancer. 
 
Inclusion criteria 
Patients were included in the analysis if they had primary non-small cell lung cancer or 
small cell lung cancer, were admitted to a hospital study site at least once within the last 6 
months of life, and died in 2013. A hospital admission was defined as an encounter in which a 
patient received continuous care at the hospital as an inpatient. 
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Exclusion criteria 
Any patient who received care exclusively as an outpatient in a study site was excluded 
from the study. Patients who died in hospital were excluded. Patients were excluded if the 
hospital admission was unrelated to the lung cancer (e.g. road traffic accident). 
 
Data sources 
Data relating to patient deaths, cancer type and staging were obtained from either the 
electronic medical record (MD Anderson) or from cancer registries linked to the study site 
(Newcastle). Patient and medication data were then extracted from each hospital computer 
system and included the following: medications on admission, medications on discharge, 
length of hospital admission, number of hospital admissions in last 6 months of life, and co-
morbidities. Each medication was classified according to British National Formulary (BNF) 
category; all continuous and ‘when required’ medications were included in the analysis. 
Preventative medication with questionable benefit was defined in one of five categories: 
vitamins and minerals, anti-diabetic, anti-hypertensive, anti-lipid, and anti-platelet 
medications, based on a previous systematic review.[7] Co-morbidity was calculated according 
to the Charlson Comorbidity Index, although for our calculations, we removed the scores 
related to tumour without metastases, and metastatic solid tumour for lung cancer, but included 
other cancers.[15] 
 
Outcome measures 
The primary outcome in this study was the number of preventative medicines 
prescribed on hospital discharge. We defined preventative medicines as drugs for diabetes, 
hypertension, hyperlipidemia, antiplatelet agents, and vitamins/minerals. We included clinical 
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and demographic variables, hospitalization variables, and medication use variables as possible 
predictors of discharge preventative medicine use.  
 
Statistical analysis 
Patient age, gender, cancer diagnosis, cancer stage, Charlson Comorbidity Index, 
hospital length of stay, length from discharge to death, and the number of preventative 
medicines used in each category, were stratified by the US and the UK cohorts. Means, 
medians, standard deviation, and range for each measure were reported. The McNemar test 
was then used to compare preventative medicine use at admission and at discharge to determine 
whether there was a significant difference in the proportion of patients taking any preventative 
medicine or preventative medicines in each of the five categories. In multivariable analysis, we 
conducted the same analyses for the UK and the US cohorts. With the outcome of number of 
preventative medicines on discharge, we constructed zero-inflated negative binomial 
regression models to account for excess zeros in the number of preventative drugs at discharge. 
The decision to use a zero-inflated negative binomial regression model was made a priori based 
on our understanding of the data. We first built models based on groups of variables, including 
clinical and demographic variables (age died, gender, cancer type, cancer stage, comorbidity), 
hospital variables (length of stay, number of hospitalizations in the last 6 months of life), and 
medication use (total preventative medicine use at admission and preventative medicine use in 
each of the 5 categories at admission and discharge, as well as total medicine use at admission 
and discharge). Except for gender, cancer type, cancer stage, comorbidity, receipt of types of 
preventative medicines (yes/no), the remaining variables were continuous. For the US data 
only, we included palliative care consultation as a single, ungrouped variable in the models. 
We built stepwise models by adding these groups of variables and did stepwise deletion by 
groups of variables and then further by individual variables, retaining variables in the model 
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with p<0.1. The likelihood ratio test was used to compare models at each step (Appendix 1). 
The final US and UK models had some important differences in significant variables, and we 
took a final step to investigate whether similar models were appropriate for both sets of data. 
A p<0.05 was considered statistically significant. All analyses were conducted separately for 
the UK and US cohorts. The UK data were analysed using SAS version 9.1, and the US data 
were analysed using STATA version 14. No statistical comparisons were made between the 
two cohorts.  
 
Results 
Participant Characteristics  
In 2013, a total of 185 lung cancer patients died who received care in the UK study site, 
whilst 349 died in the US study site. From the UK data, 19 patients died 6 months after their 
last hospital admission, 37 patients died in hospital, and 4 patients had missing data (cancer 
stage, information relating to medications on admission, and information relating to 
medications on discharge). From the US data, 109 patients died in hospital, 29 were treated 
only in the ER or on observation status without inpatient admission, 14 had cancers other than 
non-small cell or small cell lung cancer, 3 patients had admissions unrelated to lung cancer, 
and 3 patients had missing data. In total, there were 125 patients (UK) and 191 patients (US) 
included in the analysis.  
 
Characteristics  
The median patient age was 73 years for the UK site (range 48-98 years), and 65 years 
for the US site (range 22-90 years); there were more males than females for both study sites, 
whilst the majority of people presented with stage IV lung cancer; non-small cell cancer lung 
cancer (NSCLC) was more common than small cell lung cancer (SCLC).  Of the UK cohort, 
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62.4% had a Charlson score of 1 or higher, and 52.4% of the US cohort had a score of 1 or 
higher (Table 1). 
In the last 6 months of life, repeated hospital admissions were common at both study 
sites: for the UK site, the mean number was 2.0 (SD ± 1.0), whilst for the US site, the mean 
number was 1.9 (SD ± 1.0). The mean length of each hospital admission was 10.9 days (SD ± 
9.0) for the UK site, and 7.8 days for the US site (SD ± 7.4), whilst patients at both sites, on 
average, lived around 6 weeks after their last hospital admission. Polypharmacy, defined as 5 
≥ medications, was also common at both sites (observed in 81.6% and 93.7% of individuals 
admitted to hospital at UK and US sites, respectively), with the total number of medications 
increasing after each hospital admission (Table 2). 
 
Preventative medication   
The mean number of preventative medications on admission was 1.9 (SD ± 1.7) and 
2.6 (SD ± 2.2) and, for discharge, the mean number was 1.7 (SD ± 1.7) and 1.9 (SD ± 2.2) for 
UK and US sites, respectively. On admission, approximately 73 per cent of patients received a 
preventative medication for the UK site, whilst for the US site approximately 80 per cent of 
patients received a preventative medication. Overall, the number of preventative medications 
reduced at discharged to 63 per cent for the UK site, and 69 per cent for the US site; this change 
was significant for UK and US sites (Table 3). The most common prescribed preventative 
medication were the anti-hypertensive agents at the UK site, and vitamin and minerals at the 
US site; the least common prescribed medications were the anti-diabetic agents, which was 
apparent for both sites. All prescribed preventative medication categories reduced after 
discharge, apart from anti-diabetic agents and vitamins and minerals (UK), which increased, 
although this was not statistically significant, and anti-hypertensive medication (US), which 
remained constant.  
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Modeling variables 
Overall, the mean number of preventative medications was less on hospital discharge 
compared to admission. When we examined how preventative medication at discharge was 
related to other factors, the zero-inflated negative binomial regression model found a 
significant positive association between the number of preventative drugs on admission and 
the number of preventative medications on discharge; for example, in the UK model, for every 
1 preventative drug at admission, the number of preventative medications at discharge will 
increase by 1.27, expressed as Incidence Rate Ratio (IRR) (95% confidence Intervals (CI): 
1.17, 1.39); similarly, in the US model, for every 1 preventative drug at admission, the number 
of preventative medications at discharge will increase by 1.13 IRR (95% CI: 1.06, 1.20). There 
was also a significant positive association between the total number of drugs on discharge and 
the number of preventative medications on discharge, which was evident at both UK and US 
study sites (Table 4). In the US model only, there were significant associations between total 
drugs on admission with an IRR of 0.95 (95% CI: 0.92, 0.97), having a palliative care 
consultation with an IRR of 0.73 (95% CI: 0.58, 0.92), and total medication at discharge with 
an IRR of 1.10 (95% CI: 1.08, 1.13). None of the other indicators (age, cancer stage, cancer 
type, co-morbidity, length of hospital admission, number of hospitalizations) were significantly 
associated with preventative medications on discharge, and their addition/removal did not 
significantly affect our models (Appendix 2). 
 
Discussion 
This paper is the first to describe the prescribing of preventative medication in a cohort 
of lung cancer patients at hospital admission and discharge  across different healthcare systems. 
We have identified a number of key findings that may be of importance to healthcare 
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practitioners and policy makers: (1) for lung cancer patients who are admitted to hospital, 
polypharmacy is common; (2) the mean number of medications a hospitalized lung cancer 
patient is prescribed increases after hospital admission; (3) the prescribing of preventative 
medications is common amongst hospitalized lung cancer patients; and, (4) patient factors 
(such as age, cancer stage, cancer type, co-morbidity, and number of days between discharge 
and death) and hospital factors (such as length of hospital admission, and number of 
hospitalizations) were not associated with the prescribing of preventative medication. 
While this is the first study to specifically assess prescribing of preventative medication 
in lung cancer patients, other studies have explored prescribing and medicines use for patients 
who are at end of life. Currow and colleagues, for example, showed that, in a cohort of 
palliative care patients, as death approaches, the number of medications increases from 4.9 to 
6.4 – primarily as a result of people using more symptom specific medications.[16] Of note, 
the same study also showed the number of potentially inappropriate medications, as assessed 
using the Beers criteria, also increased as death approaches.[16] Other studies have explored 
the prescribing of specific classes of medication in the context of limited life expectancy: for 
example, Pearson and colleagues showed more than 30 per cent of cancer patients were 
dispensed statins within 30 days of death,[17] whilst Bayless and colleagues revealed, in a 
cohort of cancer patients, more than 60 per cent of individuals continued with statin therapy 
for 2 years after their diagnosis.[18] Our findings lend support to the literature, and show that 
lung cancer patients who are admitted to hospital are commonly discharged with preventative 
medication; this appears to have been the continuation of current medication, as opposed to 
initiating new preventative medication. 
In terms of developing an intervention to reduce polypharmacy and rationalize 
medications in lung cancer patients – or possibly other life limiting illnesses – this work is 
significant. Indeed, our work shows that the point of discharging a patient from hospital might 
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be an appropriate place to develop an intervention to reduce – or to start the process of reducing 
– burdensome preventative medication that is no longer appropriate given a patient’s reduced 
life expectancy. Further work should explore the nature of the intervention, but it is 
encouraging that, at the US site, a consultation with a palliative care clinician did appear to be 
associated with less preventative medication on discharge. This is consistent with a previous 
study in the inpatient palliative care unit at the same US setting that found among 100 
consecutive patients admitted to the unit, medications increased from a mean of 9.2 to 10.1, 
with an increase in symptomatic medications and a reduction in medications for comorbid 
conditions.[19] 
Previous literature has also shown that a pharmacist intervention at the point of 
discharging has reduced the level of inappropriate prescribing in a general older 
population.[20-21] Given the important role of clinical pharmacists in both UK and US 
discharge processes, they should play a key role in delivering any intervention aimed at 
reducing inappropriate medication in this patient population. It is clear, however, that any such 
intervention to reduce inappropriate or burdensome medication should embrace the principles 
of deprescribing. Indeed, the term ‘deprescribing’, recently defined by Reeve and colleagues, 
as the process of withdrawal of an inappropriate medication, supervised by a health care 
professional with the goal of managing polypharmacy and improving outcome,[22] has 
received a great deal of recent attention in the literature. The process of deprescribing has 
recently been reviewed,[23] and the literature suggests that in order to achieve a successful 
outcome many factors need to be considered, including patient-based (e.g. patient 
misalignment with goals of care),[24] and those involving the caregiver.[25] Another issue 
toward deprescribing is the lack of robust evidence demonstrating the effectiveness of 
deprescribing preventative medication in patients with life limiting illness. Page and colleagues 
have shown that deprescribing in older adults appears to be safe and feasible,[26] although, to 
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date, Kutner and colleagues are the only group to publish a randomised clinical trial specifically 
addressing the issue of deprescribing medication in people with life limiting illness. The trial, 
which discontinued statin therapy in a cohort of patients with advanced life limiting illness, 
showed that stopping statin therapy is safe, and is associated with reduced costs and improved 
quality of life.[27] Given the high prevalence of other preventative medication identified in our 
cohort of patients, other trials, exploring the cessation of antihypertensive agents, and anti-
diabetic agents appear to be warranted. A small scale study has, however, shown many 
palliative care patients with previously diagnosed hypertension despite having low blood 
pressure, and, in some cases, symptoms of postural hypotension, are still using antihypertensive 
medication.[28]  
While we believe our results are robust, and have important implications for the way in 
which medications are prescribed to lung cancer patients, we do acknowledge our work has 
several limitations: firstly, we did not assess the appropriateness of preventative medication, as 
we just reported on the prescribing. It is possible that some of the preventative medication was 
prescribed appropriately (for example, ACE inhibitors in the case of advanced heart failure); 
secondly, only including lung cancer patients who were admitted to hospital, may not give a 
true account of the medication histories for all lung cancer patients, given that it is possible that 
those admitted to hospital had more complex medication regimens. We do not know if patients 
were discharged with a plan for medication reduction after discharge. We also were not able to 
collect information on site of discharge or discharge to hospice care, which might be 
particularly important in the US cohort. We would, therefore, urge that our results are 
interpreted in view of these limitations. In terms of study strengths, we believe that collecting 
data across two healthcare systems (the UK, and the US) is a key strength of the study, and this 
adds international context to our work. 
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Conclusion 
Polypharmacy is common in hospitalised lung cancer patients; the use of preventative 
medication remained high among such patients, despite undergoing hospital discharge. Patient-
based and hospital-based factors did not influence the prescribing of preventative medication. 
There may be scope to develop an intervention that embraces the principles of deprescribing at 
the point of hospital discharge to reduce inappropriate prescribing in lung cancer patients. 
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Table 1: Study participant characteristics for UK and US sites 
  UK (%) 
n=125 
US (%) 
n=191 
    
Gender  Female 48.8 46.6 
 Male 51.2 53.4 
 
Cancer type NSCLC 85.6 86.4 
 SCLC 14.4 11.5 
 Other 0.0 2.1 
 
Staging 1A 0.8 2.1 
 1B 3.2 0.0 
 IIA 1.6 0.0 
 IIB 1.6 0.5 
 IIIA 8.8 6.8 
 IIIB 16.0 2.6 
 IV 68.0 88.0 
 
Charlson co-morbidity 
index 
0 37.6 47.6 
 1 44.8 23.6 
 2 9.6 17.3 
 3 6.4 6.8 
 4 0.8 2.1 
 5 0.0 1.6 
 6 0.8 0.0 
 7 0.0 0.5 
 8 0.0 0.5 
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Table 2: Hospital admission and discharge characteristics for study participants 
 
 UK (n=125) US (n=191) 
 
Indicator Mean, SD Median Range 
 
Mean, SD Median Range 
Age (years) 72.8 ± 10.5 73 48-98 63.8 ± 10.9 65 22-90 
 
Length of hospital admission (days) 
 
10.9 ± 9.0 
 
8 
 
1-37 
 
7.8 ± 7.4 
 
6 
 
1-49 
Number of hospital admission within 6 
months of life 
2.0 ± 1.0 2 1-5 1.9 ± 1.4 1 1-10 
Number of days discharged before death 
 
43.3 ± 46.0 28 1-178 38.4 ± 40.7 22 1-190 
Total preventative drugs on admission 1.9 ± 1.7 2 0-7 2.6 ± 2.2 2 0-10 
Total preventative drugs at discharge 1.7 ± 1.7 2 0-7 1.9 ± 2.0 1 0-8 
 
Total drugs on admission 
 
8.8 ± 3.8 
 
9 
 
1-18 
 
11.6 ± 5.0 
 
11 
 
0-26 
Total drugs discharge 10.3 ± 4.3 11 1-20 12.1 ± 4.7 12 2-28 
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Table 3: Number of patients with preventive medication at admission and at discharge. 
 UK (n=125)  US (n=191) 
 
 
Preventive Medicine Type N (%) at 
admission 
N (%) at 
discharge 
P-valuea N (%) at 
admission 
N (%) at 
discharge 
 
P-valuea 
Anti-diabetic 8 (6.4) 11 (8.8) 0.375 23 (12.0) 21 (11.0) 0.75 
Anti-hypertensives 59 (47.2) 44 (35.2) 0.001 97 (50.8) 97 (50.8) 1.000 
Anti-lipid 57 (45.6) 40 (32.0) <0.001 61 (31.9) 44 (23.0) 0.032 
Anti-platelet 38 (30.4) 30 (24.0)  0.057 39 (20.4) 33 (17.3) 0.307 
Multivitamins and minerals 30 (24.0) 36 (28.8) 0.286 106 (55.5) 73 (38.2) <0.001 
Any preventive medicine 91 (72.8) 79 (63.2) 0.017 152 (79.6) 132 (69.1) 0.002 
adifference between number at admission and number at discharge, using the McNemar test 
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Table 4. Zero inflated negative binomial regression models examining association between 
of total preventative drug at discharge with related factors.  
 
 United Kingdom (n=125) 
 
Indicator IRR, 95% CI 
 
0.99 (0.97-1.01) 
0.95 (0.90-1.01) 
1.08 (1.03-1.14) 
1.27 (1.17-1.39) 
 
Number of days admitted 
Total drugs at admission 
Total drugs at discharge 
Total preventative drugs at admission 
 
 United States (n=191) 
 
Indicator IRR, 95% CI 
 
0.73 (0.58-0.92) 
0.95 (0.92-0.97) 
1.33 (1.18-1.50) 
1.10 (1.08-1.13) 
1.13 (1.06-1.20) 
1.25 (1.00-1.54) 
 
Palliative care consultation 
Total drugs at admission 
Hypertensive drugs at admission 
Total drugs at discharge 
Total preventative drugs at admission 
Anti-platelet drugs at admission 
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Appendix 1. Likelihood ratio test comparing the saturated model and final model to ensure 
that no substantial loss of information between the saturated model and the final most 
parsimonious model 
 
Country Models -2 Log 
likelihood 
 (-2LL) 
# parameters df Difference 
in -2LL 
P value 
UK Saturated model 303.580 22 18 8.579 0.968 
Final model 312.159 4    
US Saturated model 592.561 24 19 -40.441 1.000 
Final model 552.012 5    
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Appendix 2a. Type 3 test from zero inflated negative binomial regression models for 
variables not included in the final model for UK data  
 
 UK data 
Indicators DF Chi-
square 
P value  
Gender 1 0.07 0.785 
Age  1 0.49 0.486 
Cancer type 1 0.01 0.931 
Cancer stage 7 2.14 0.952 
Comorbidity 1 0.04 0.849 
Length of hospital admission 1 3.18 0.075 
Number of hospitalizations 1 0.20 0.657 
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Appendix 2b.  Negative binomial regression results for variables not included in the final 
model for US data 
 
Indicators Chi-square P value 
Gender 1.40 0.163 
Age -0.19 0.848 
Cancer type 
   Small cell lung cancer 
   Other 
 
1.28 
-0.83 
 
0.202 
0.406 
Cancer stage 
   IIB 
   III 
   IIIB 
   IV 
 
0.80 
1.31 
1.17 
0.71 
 
0.422 
0.189 
0.241 
0.480 
Comorbidity (CCI) 
   1 
   2 
   3 
   4 
   5 
   7 
   8 
 
1.35 
0.53 
1.55 
0.88 
1.26 
-0.11 
0.67 
 
0.175 
0.596 
0.121 
0.380 
0.207 
0.908 
0.505 
Length of hospital admission 0.42 0.673 
Number of hospitalizations 0.57 0.569 
Number of diabetes medications at admission -1.50 0.133 
Number of lipid lowering drugs at admission -2.07 0.038 
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Appendix 3. Variance Inflation factor to check for multicollinearity between the variables 
included in the final model. Value between 1 and 10 are considered acceptable (Kutner MH, 
Nachtsheim C, Neter J. (2004). Applied linear regression models. McGraw-Hill/Irwin. 
 
Variables 
Variance Inflation Factor (VIF) 
UK data US data 
Length of admission (days) 1.027 - 
Number of drugs on admission 2.091 1.86 
Total preventative drugs 
(admission) 
1.321 
2.41 
Number of drugs on discharge 1.766 1.53 
Palliative care consultation - 1.11 
Hypertensive drugs (admission) - 1.63 
Antiplatelet drugs (admission) - 1.29 
   
 
 
